# Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Source: https://onco.cc/trials/nct06483555/  
OnCo record `nct06483555` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of gemcitabine, nab-paclitaxel, erlotinib, nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) and other drugs in pancreatic cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.

## Summary

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel is a phase 1/2, interventional study registered as NCT06483555 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 104 participants, started 2025-02-06 and due to reach its primary completion in 2027-08. Interventions recorded: Gemcitabine; Nab paclitaxel; Erlotinib; NALIRIFOX; Folfirinox. Conditions listed: Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm. Primary outcome: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE); Dose-limiting toxicity (DLT); Overall survival- classical metastatic pancreatic adenocarcinoma. Pancreatic eligibility wording from the registry: "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 Histological or cytological evidence/confirmation of unresectable, borderline resectable, or metastatic (basal-like and classical) pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PANGEA
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06483555
- Phase: 1/2
- Setting: Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.
- Sponsor: UNC Lineberger Comprehensive Cancer Center
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT06483555: https://clinicaltrials.gov/study/NCT06483555

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Erlotinib](https://onco.cc/drugs/erlotinib/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06483555.json